Navigation Links
Resverlogix Board of Directors Update
Date:9/3/2008

t they will result in any specific transaction that will be acceptable to the Company. Management and the Board of Directors will continue to monitor ongoing developments and update the market when deemed appropriate or required.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production within one's own body. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast
2. Jan Gray Joins Resverlogix Board of Directors
3. Resverlogixs Lead Drug Featured in Key Scientific Publication
4. Industry Leaders Select Resverlogixs RVX-208
5. /C O R R E C T I O N from Source -- Resverlogix Corp./
6. Resverlogix Notice of Conference Call & Webcast
7. Resverlogix Share Option Extension
8. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
9. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
10. Resverlogix is Presenting at IAS HDL Workshop
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Modeling Complex ... Biological Systems for Type 2 Diabetes, CAMBRIDGE, Mass., ... on identifying molecular mechanisms, networks and,biomarkers to better understand ... Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company ...
... CHURCH, Va., April 30 Computer Sciences,Corporation (NYSE: ... M. Wah, chief,medical officer and vice president of ... ranked number 10 in Modern Physician and Modern,Healthcare ... Physician,Executives, published in April. Readers from both magazines ...
... XI,AN, China, April 30 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical ... leading,developer and producer of plant extracts and ... and food production, today,announced that it will ... March 31 on Thursday, May 15, 2008, ...
Cached Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... April 16, 2014. Kessler Foundation has been named ... from the Department of Defense Spinal Cord Injury ... investigator for the randomized, double-blinded, controlled, multi-site clinical ... and muscle strength after spinal cord injury. Dr. ... Engineering Research at Kessler Foundation. Two additional sites ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... have extraordinarily small balance organs, and scientists have long ... School of Medicine in St. Louis has contradicted a ... heads so vigorously that they had to have smaller, ... Working with a Midwestern zoo and a local ...
... be promising candidates for drug development has become easier ... medicinal chemistry group. Dr Jonathan Baell and Dr ... can be used to weed out those molecules likely ... chemical library for compounds that could be useful in ...
... ─ The National Institutes of Health has awarded Albert ... to combat childhood obesity in the Bronx. Working with ... Center for Einstein, a team of researchers will build ... the classroom to encourage physical activity and promote positive ...
Cached Biology News:Rodeo bull goes head-to-head with zoo dolphins in a study of balance 2Rodeo bull goes head-to-head with zoo dolphins in a study of balance 3Compound screening for drug development made simpler 2Einstein-Montefiore research tackles childhood obesity in the Bronx 2Einstein-Montefiore research tackles childhood obesity in the Bronx 3